Latest Presentation
Recent Event
American Society of Cataract and Refractive Surgery 2022
Latest Financial Results
FY 2021

Latest Annual Filing
For Fiscal Year Ending Dec 31, 2021
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.

Company Overview
Kiora is a clinical-stage biotechnology company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing..
IR Contacts
Company
Kiora Pharmaceuticals, Inc.
1371 East 2100 South
Suite 200
Salt Lake City, UT 84105
Investor Relations
Francina Agosti, PhD
T: 617-546-0742
fagosti@reportablenews.com